Cargando…
Targeting CXCL1 chemokine signaling for treating cisplatin ototoxicity
Cisplatin is chemotherapy used for solid tumor treatment like lung, bladder, head and neck, ovarian and testicular cancers. However, cisplatin-induced ototoxicity limits the utility of this agent in cancer patients, especially when dose escalations are needed. Ototoxicity is associated with cochlear...
Autores principales: | Al Aameri, Raheem F. H., Alanisi, Entkhab M. A., Oluwatosin, Adu, Al Sallami, Dheyaa, Sheth, Sandeep, Alberts, Ian, Patel, Shree, Rybak, Leonard P., Ramkumar, Vickram |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Frontiers Media S.A.
2023
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10102581/ https://www.ncbi.nlm.nih.gov/pubmed/37063917 http://dx.doi.org/10.3389/fimmu.2023.1125948 |
Ejemplares similares
-
Tonic suppression of PCAT29 by the IL-6 signaling pathway in prostate cancer: Reversal by resveratrol
por: Al Aameri, Raheem F. H., et al.
Publicado: (2017) -
Mechanisms of Cisplatin-Induced Ototoxicity and Otoprotection
por: Sheth, Sandeep, et al.
Publicado: (2017) -
Capsaicin Protects Against Cisplatin Ototoxicity by Changing the STAT3/STAT1 Ratio and Activating Cannabinoid (CB2) Receptors in the Cochlea
por: Bhatta, Puspanjali, et al.
Publicado: (2019) -
Epigallocatechin-3-gallate, a prototypic chemopreventative agent for protection against cisplatin-based ototoxicity
por: Borse, Vikrant, et al.
Publicado: (2017) -
Regulator of G protein signaling 17 represents a novel target for treating cisplatin induced hearing loss
por: Dhukhwa, Asmita, et al.
Publicado: (2021)